Desmoid Tumors Market, By Drug Type (Non-steroidal anti-inflammatory drugs(NSAIDs), Targeted Therapy, Chemotherapy, Hormone Therapy, Others), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Retail Pharmacies), and By Geography (Asia-Pacif

Desmoid Tumors Market, By Drug Type (Non-steroidal anti-inflammatory drugs(NSAIDs), Targeted Therapy, Chemotherapy, Hormone Therapy, Others), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Retail Pharmacies), and By Geography (Asia-Pacific , North America, Europe, South America, Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

A desmoid tumor is an abnormal growth that arises from connective tissue, which is the tissue that provides strength and flexibility to structures such as bones, ligaments, and muscles. Desmoid tumors are fibrous, much like scar tissue. They are generally not considered cancerous (malignant) because they do not spread to other parts of the body. However, they can aggressively invade the surrounding tissue and can be very difficult to remove surgically. These tumors often recur, even after apparently complete removal. The most common symptom of desmoid tumors is pain. Other signs and symptoms, which are often caused by growth of the tumor into surrounding tissue, vary based on the size and location of the tumor.

Market Dynamics

Key players operating in the market are focused on developing drugs for the treatment of desmoid tumors which is expected to drive the market growth over the forecast period. For instance, in July 2022, Ayala Pharmaceuticals, Inc., a clinical-stage oncology company focusing on discovering and commercializing small molecule medicines for patients with uncommon tumors and aggressive cancers, announced positive interim findings from Part A of the ongoing RINGSIDE Pivotal Phase 2/3 clinical study assessing AL102 in desmoid tumors. AL102 is an oral gamma-secretase inhibitor that is powerful and specific GSI. Moreover, the presence of desmoid tumor foundation providing funds for desmoid tumor research, is expected to drive the market growth in the country over the forecast period. For instance, Desmoid Tumour Foundation of Canada (DFC) is a registered Canadian charity dedicated to funding research for cure for desmoid tumors. DFC is dedicated to funding desmoid tumor research and finding a cure for this rare disease. DFC supports the collaboration between researchers from different institutions to expedite the development of cure.

Key features of the study:

• This report provides an in-depth analysis of the global desmoid tumor market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global desmoid tumor market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies.
• Key companies covered as a part of this study Horizon Therapeutics Plc, Strides Pharma Science Limited, Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Hikma Pharmaceuticals PLC, Natco Pharma Ltd, Lupin, Zydus Lifesciences, Mylan N.V., Assertio Holdings, Inc., Mayne Pharma Group Limited, Alembic Pharmaceuticals Limited, Aprazer, Ayala Pharmaceuticals, SpringWorks Therapeutics, Inc., Iterion Therapeutics, Novartis AG, Apotex Inc., Bayer AG., Sun Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd., Endo International plc, Abbott, and Getwell Pharmaceuticals
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global desmoid tumor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Desmoid Tumors Market.

Detailed Segmentation:

• Global Desmoid Tumors Market, By Drug Type:
• Non-steroidal anti-inflammatory drugs (NSAIDs)
• Targeted Therapy
• Chemotherapy
• Hormone Therapy
• Others
• Global Desmoid Tumors Market, By Distribution Channel :
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Global Desmoid Tumors Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Horizon Therapeutics Plc.*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Strides Pharma Science Limited
• Teva Pharmaceutical Industries Ltd.
• Amneal Pharmaceuticals LLC
• Hikma Pharmaceuticals PLC
• Natco Pharma Ltd
• Lupin
• Zydus Lifesciences
• Mylan N.V.
• Assertio Holdings, Inc.
• Mayne Pharma Group Limited
• Alembic Pharmaceuticals Limited
• Aprazer
• Ayala Pharmaceuticals
• SpringWorks Therapeutics, Inc.
• Iterion Therapeutics
• Novartis AG
• Apotex Inc.
• Bayer AG
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories Ltd.
• Endo International plc
• Abbott
• Getwell Pharmaceuticals

“*” marked represents similar segmentation in other categories in the respective section.